Author:
Vicentini Carlo,Festuccia Claudio,Gravina Giovanni Luca,Angelucci Adriano,Marronaro Angelo,Bologna Mauro
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference56 articles.
1. Arteaga CL, Johnson DH (2001) Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr Opin Oncol 13:491–498
2. Baselga J, Averbuch SD (2000) ZD1839 ('Iressa') as an anticancer agent. Drugs 60 [Suppl 1]:33–42
3. Baselga J, LoRusso P, Herbst R, Rischin D, Ranson M, Maddox AM, Averbuch SA (1999) Pharmacokinetic/pharmacodynamic trial of ZD1839 ('Iressa'), a novel oral epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitor, in patients with 5 selected tumor types (a Phase I/II trial of continuous once-daily treatment). Clin Cancer Res 5 [Suppl]:(abstr 29)
4. Bologna M, Vicentini C, Festuccia C, Muzi P, Napolitano T, Biordi L, Miano L (1988) Short-term tissue culture of prostatic carcinoma samples provides useful biological parameters related to patient prognosis. Eur Urol 15:243–247
5. Bologna M, Festuccia C, Muzi P, Biordi L, Ciomei M (1989) Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer 63:1714–1720
Cited by
69 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献